{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:05:21Z","timestamp":1793325921278,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtho.2025.10.009","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:28:16Z","timestamp":1761121696000},"page":"318-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1185","authenticated-orcid":false,"given":"Xiuning","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus","family":"Johannes de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula G.","family":"Fraenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brayan Merchan","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Ho","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.10.009_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.10.009_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.10.009_bib3","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1200\/JCO-24-02133","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, version 2024.2","volume":"42","author":"Bazhenova","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2025.10.009_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib6","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"Jia","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtho.2025.10.009_bib7","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1158\/1078-0432.CCR-18-1189","article-title":"First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity","volume":"25","author":"Gan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.009_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.10.009_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","article-title":"Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (Orchard)","volume":"22","author":"Yu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2025.10.009_bib11","author":"Ahn","year":"2022","journal-title":"MET Biomarker-Based Preliminary Efficacy Analysis in SAVANNAH: Savolitinib + Osimertinib in EGFRm NSCLC Post-Osimertinib. Poster Presented at WCLC"},{"key":"10.1016\/j.jtho.2025.10.009_bib12","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib15","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (Insight 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib18","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2023.41.16_suppl.9013","article-title":"Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: analysis of tissue IHC and ctDNA NGS","volume":"41","author":"Besse","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib19","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1111\/cas.14180","article-title":"SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met","volume":"110","author":"Tong","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2025.10.009_bib20","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.10.009_bib21","article-title":"Brief report: clinical response, toxicity, and resistance mechanisms to osimertinib plus MET inhibitors in patients with EGFR-mutant MET-amplified NSCLC","volume":"4","author":"Wang","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.10.009_bib22","article-title":"Orchard: osimertinib plus necitumumab in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer with a secondary epidermal growth factor receptor alteration whose disease had progressed on first-line osimertinib","volume":"9","author":"Riess","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.10.009_bib23","article-title":"Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer","volume":"3","author":"Suzawa","year":"2019","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:17Z","timestamp":1778819297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425028564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1556086425028564"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.10.009","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}